210 related articles for article (PubMed ID: 24335343)
1. Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker.
Butterfield JH; Weiler CR
Int Arch Allergy Immunol; 2014; 163(2):130-4. PubMed ID: 24335343
[TBL] [Abstract][Full Text] [Related]
2. [Vulvar oedema revealing systemic mastocytosis].
Deveza E; Locatelli F; Girardin M; Valmary-Degano S; Daguindau E; Aubin F; Humbert P; Pelletier F
Ann Dermatol Venereol; 2015 Nov; 142(11):685-9. PubMed ID: 26003033
[TBL] [Abstract][Full Text] [Related]
3. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
4. Recurrent syncope and anaphylaxis as presentation of systemic mastocytosis in a pediatric patient: case report and literature review.
Shaffer HC; Parsons DJ; Peden DB; Morrell D
J Am Acad Dermatol; 2006 May; 54(5 Suppl):S210-3. PubMed ID: 16631942
[TBL] [Abstract][Full Text] [Related]
5. Interactive medical case. A rash hypothesis.
Ross JJ; Saavedra A; Vleugels RA; Liu A; Castells MC
N Engl J Med; 2010 Jun; 362(24):e69. PubMed ID: 20560180
[No Abstract] [Full Text] [Related]
6. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
Divekar R; Butterfield J
Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
[TBL] [Abstract][Full Text] [Related]
7. [Systemic mastocytosis. Classification, symptoms, therapy].
Kraemer DM; Grunewald SM; Kolb-Mäurer A
Med Klin (Munich); 2004 Mar; 99(3):131-6. PubMed ID: 15024485
[TBL] [Abstract][Full Text] [Related]
8. Childhood mastocytosis.
Torrelo A; Alvarez-Twose I; Escribano L
Curr Opin Pediatr; 2012 Aug; 24(4):480-6. PubMed ID: 22790101
[TBL] [Abstract][Full Text] [Related]
9. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
10. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
[TBL] [Abstract][Full Text] [Related]
11. [Systemic mastocytosis].
Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
[TBL] [Abstract][Full Text] [Related]
12. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions.
van Doormaal JJ; van der Veer E; van Voorst Vader PC; Kluin PM; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; Oude Elberink JN; de Monchy JG
Allergy; 2012 May; 67(5):683-90. PubMed ID: 22435702
[TBL] [Abstract][Full Text] [Related]
13. [IgE mediated anaphylaxis in a patient with systemic mastocytosis].
Escande H; Bennani I; Bulai Livideanu C; Uthurriague C; Paul C; Nougué J
Ann Dermatol Venereol; 2013 Oct; 140(10):641-4. PubMed ID: 24090896
[TBL] [Abstract][Full Text] [Related]
14. Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
Marbello L; Anghilieri M; Nosari A; Minola E; Cairoli R; Ricci F; Morra E
Haematologica; 2004 Sep; 89(9):ECR35. PubMed ID: 15377487
[TBL] [Abstract][Full Text] [Related]
15. Increased leukotriene E4 excretion in systemic mastocytosis.
Butterfield JH
Prostaglandins Other Lipid Mediat; 2010 Jun; 92(1-4):73-6. PubMed ID: 20380889
[TBL] [Abstract][Full Text] [Related]
16. Mastocytosis.
Abid A; Malone MA; Curci K
Prim Care; 2016 Sep; 43(3):505-18. PubMed ID: 27545739
[TBL] [Abstract][Full Text] [Related]
17. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
18. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
Castells M; Butterfield J
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1097-1106. PubMed ID: 30961835
[TBL] [Abstract][Full Text] [Related]
19. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis.
Turner PJ; Kemp AS; Rogers M; Mehr S
Pediatr Dermatol; 2012; 29(2):222-3. PubMed ID: 22044360
[TBL] [Abstract][Full Text] [Related]
20. Multimodal therapy for vertebral involvement of systemic mastocytosis.
Krüger A; Hamann C; Brendel C; Ramaswamy A; Schnabel M; Neubauer A; Hofbauer LC
Spine (Phila Pa 1976); 2009 Aug; 34(17):E626-8. PubMed ID: 19644322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
